Successful treatment of Helicobacter pylori infection is becoming compromised by emerging resistance. We report the prevalence rates of H. pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. A total of 231 H. pylori clinical isolates were collected throughout the country over a period of 6 months during 1997-1998. The MICs of the above-mentioned antibiotics were determined in a single laboratory. The overall percentage of resistance for clarithromycin and metronidazole was 1.7% and 21.2%, respectively. None of the strains was resistant to amoxycillin or tetracycline. The primary resistance rate of trovafloxacin was as high as 4.7%. Since trovafloxacin has not yet been introduced on to the Dutch market, the resistance is probably induced by the use of other quinolones. Our data indicate that treatment outcome would benefit from susceptibility testing before starting therapy, especially when prescribing metronidazole.
Introduction
Helicobacter pylori eradication treatment is indicated in all patients with active or recurrent peptic ulceration. 1 Eradication treatment usually consists of a proton pump inhibitor (PPI), or an H 2 -antagonist in combination with two antibiotics. 2 The rationale behind the combination of two antibiotics is in the increased success of the eradication therapy and the decreased rates at which secondary antibiotic resistance develops. 3 Commonly used agents for treatment of H. pylori infections include clarithromycin, metronidazole, amoxycillin and tetracycline. An increase in resistance to these agents is to be expected due to the growing numbers of patients treated, poor patient compliance and an increased use of antibiotics in the last few years. The prevalence of clarithromycin, metronidazole and amoxycillin resistance varies between countries and is the highest for metronidazole. [4] [5] [6] [7] [8] Resistance to tetracycline has been reported but appears uncommon. 9 Treatment for H. pylori infection is often started on an empirical basis; if the infecting strain is resistant, successful eradication is compromised. Therefore it is important to be informed about the antibiotic resistance of H. pylori locally. For this reason we studied the prevalence of antibiotic resistance of H. pylori in The Netherlands. Trovafloxacin is a new fluoroquinolone and, although it is not yet approved for treatment of H. pylori infections, it might be a promising candidate 10, 11 and, therefore, was included in the study. We also studied whether resistance rates were related to an increased use of antibiotics in the last few years. 
Materials and methods

Strains and growth conditions
Consumption of macrolide antibiotics and metronidazole
Data on the consumption of macrolide antibiotics and metronidazole were obtained from the 'Stichting Farmaceutische Kengetallen The Hague, The Netherlands'.
Interregional differences in antibiotic consumption and resistance rates
To obtain an insight into potential interregional differences in antibiotic consumption and resistance rates, we divided The Netherlands into three regions, namely West, NorthEast and South regions. Patients whose strains were studied were classified into one of these three regions based on their place of residence. 
Results
The overall percentages of resistance are summarized in the Table. The antibiotic consumption of macrolides and metronidazole in The Netherlands from 1993 to 1997 is shown in Figure 2 . It is interesting to note that the consumption of clarithromycin and azithromycin increased markedly, whereas the consumption of roxithromycin remained the same. In 1997 there were no major differences in consumption for clarithromycin and metronidazole between the three regions (data not shown).
Discussion
The introduction of the new macrolide clarithromycin and the azalide azithromycin did not result in the anticipated decreased prescription rate for the older macrolide erythromycin. The increased consumption of macrolides is expected to influence the prevalence of H. pylori resistance to clarithromycin. The number of strains included in this study was too small to draw any solid conclusions on interregional differences in macrolide resistance. The observed overall percentage of resistance to clarithromycin is 1.7%; this is only marginally higher than the 1% resistance reported in 1994/1995. 7 Based on these findings, to start empirical treatment with clarithromycin is appropriate; however, development of resistance is the main reason for treatment failure with clarithromycin monotherapy. Since resistance is due to a single point mutation in the 23S rRNA gene of H. pylori, 3, 13 we strongly advise that clarithromycin should always be combined with a second anti-H. pylori drug.
Two out of a total of four clarithromycin-resistant strains in this study were also resistant to metronidazole. This number is high, since in the total bacterial population tested only one out of five (20%) strains was metronidazole resistant. High prevalence rates for double resistance may be the result of combination therapy as indicated by the findings of Buckley et al.
14 If the infecting strain is already resistant to metronidazole, the patient can be treated effectively with clarithromycin monotherapy.
Metronidazole use in The Netherlands has increased steadily over the last 4 years. We found an overall metronidazole resistance rate of 21.2%. This is 3% higher than in 1994/1995. 7 With a desired cure rate of 90%, the observed metronidazole resistance may preclude the use of this drug for empirical treatment. Our metronidazole resistance rates compare with the 32% metronidazole resistance reported by van der Wouden et al. 8 In the present study five out of 11 strains originating from the same area as those studied by van der Wouden et al. were resistant to metronidazole, and although the numbers are small this could indicate that there are regional variations in the prevalence of metronidazole resistance in The Netherlands. Metronidazole consumption in this area was similar to elsewhere in the country and so the increased incidence of resistance may be due to poor patient compliance, inadequate dosing regimens, or clonal distribution of a metronidazoleresistant strain.
Another interesting finding of our study was that in spite of the fact that trovafloxacin has not yet been introduced on 514 to the Dutch market the resistance to trovafloxacin is as high as 4.7%. Most likely the observed resistance results from induction by related quinolones. The role of trovafloxacin in the treatment of H. pylori infection needs further investigation.
In conclusion, although resistance to amoxycillin and tetracycline was not observed in this study, the resistance rates for clarithromycin and metronidazole in H. pylori in The Netherlands have increased over the last 3 years. We recommend susceptibility testing before starting therapy with metronidazole.
